Q1 2026 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2026-05-15 · accession 0001937964-26-000007
$499.4M
Reported value
50
Positions
2026-03-31
Period end
The Brief · Artia Global Partners LP · Q1 2026
AI · grounded in 13F
Artia Global Partners LP exited its position in ProShares TR II UGL, reducing its exposure by $30.1M. The fund also closed its position in uniQure NV QURE for $24.5M. On the buy side, the fund established a new position in AstraZeneca PLC AZN worth $18.8M and added Moderna Inc MRNA with a $10.2M investment.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 457669307 | INSM | INSMED INC | $102.8M | 20.6% | 628,712 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $66.9M | 13.4% | 600,747 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $45.7M | 9.16% | 279,700 | PUT | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $35.2M | 7.04% | 38,220 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $24.0M | 4.81% | 2,013,602 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $21.7M | 4.35% | 29,739 | Common | SOLE |
| G0593M107 | AZN | ASTRAZENECA PLC | $18.8M | 3.77% | 95,376 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $16.1M | 3.23% | 503,936 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $13.7M | 2.74% | 162,990 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $12.2M | 2.43% | 124,990 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $10.8M | 2.17% | 144,376 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $10.2M | 2.03% | 200,000 | CALL | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $9.9M | 1.98% | 767,098 | Common | SOLE |
| 74834L100 | DGX | QUEST DIAGNOSTICS INC | $8.0M | 1.60% | 40,817 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $7.2M | 1.43% | 325,046 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $5.9M | 1.18% | 180,731 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $5.6M | 1.12% | 46,700 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $5.5M | 1.11% | 104,800 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $5.5M | 1.11% | 22,600 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $4.8M | 0.96% | 119,741 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $4.7M | 0.95% | 96,285 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $4.3M | 0.87% | 138,508 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $4.1M | 0.81% | 17,740 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $4.0M | 0.80% | 24,989 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $3.8M | 0.76% | 65,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $3.7M | 0.75% | 137,800 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $3.6M | 0.72% | 129,800 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $3.5M | 0.70% | 1,992,367 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $3.4M | 0.68% | 18,437 | Common | SOLE |
| 74291D104 | PROK | PROKIDNEY CORP | $3.2M | 0.65% | 1,806,939 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $3.2M | 0.63% | 14,500 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP DEL | $3.0M | 0.59% | 5,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $2.8M | 0.56% | 38,407 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.4M | 0.48% | 22,931 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $2.3M | 0.46% | 68,490 | Common | SOLE |
| 10950A106 | BTSG | BRIGHTSPRING HEALTH SVCS INC | $2.3M | 0.46% | 53,800 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $2.1M | 0.42% | 70,700 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $2.1M | 0.41% | 65,500 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $1.8M | 0.36% | 15,576 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.5M | 0.30% | 20,400 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $1.4M | 0.28% | 29,200 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $1.1M | 0.22% | 16,300 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $819,280 | 0.16% | 20,900 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $805,475 | 0.16% | 2,500 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $672,859 | 0.13% | 42,080 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $648,764 | 0.13% | 17,019 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $502,005 | 0.10% | 4,900 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $495,425 | 0.10% | 5,886 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $432,522 | 0.09% | 28,970 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $363,423 | 0.07% | 205,324 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.